Arrowhead Pharmaceuticals

Yahoo Finance • 3 months ago

With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners

Key Insights Given the large stake in the stock by institutions, Arrowhead Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 9 investors have a majority stake in the company with 51% ownership Ownershi... Full story

Yahoo Finance • 4 months ago

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

- Company hosting a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT to discuss results PASADENA, Calif., August 21, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will... Full story

Yahoo Finance • 5 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

PASADENA, Calif., July 24, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fi... Full story

Yahoo Finance • 6 months ago

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing... Full story

Yahoo Finance • 8 months ago

Turnstone Biologics Appoints William Waddill to its Board of Directors

Turnstone Biologics Corp. SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure... Full story

Yahoo Finance • 8 months ago

Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses

Key Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock price is sensitive to their trading actions The top 22 shareholders own 50% of the company Insiders have sold recently If you want to know w... Full story

Yahoo Finance • 10 months ago

Arrowhead Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations

Arrowhead Pharmaceuticals (NASDAQ:ARWR) First Quarter 2024 Results Key Financial Results Revenue: US$3.55m (down 94% from 1Q 2023). Net loss: US$132.9m (loss widened by 222% from 1Q 2023). US$1.24 loss per share (further deteriorated fro... Full story

Yahoo Finance • 11 months ago

Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call

Participants Vince Anzalone; Vice President, Head of Investor Relations; Arrowhead Pharmaceuticals, Inc Christopher Anzalone; President and Chief Executive Officer; Arrowhead Pharmaceuticals, Inc Bruce Given; Chief Operating Officer; Ar... Full story

Yahoo Finance • 12 months ago

Arrowhead Pharmaceuticals Inc Insider Sells Shares

Chief Discovery/Trans Medicine James Hamilton of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) sold 38,443 shares of the company's stock on January 5, 2024, according to a recent SEC Filing. Warning! GuruFocus has detected 6 Warning Signs w... Full story

Yahoo Finance • 12 months ago

Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Anzalone sold 12,000 shares of the company's stock on December 20, 2023, according to a recent SEC filing. The transaction was executed at an average price of $28.54 per share, re... Full story

Yahoo Finance • last year

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

- Conference Call and Webcast Today, November 29, 2023, at 4:30 p.m. ET PASADENA, Calif., November 29, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended Septe... Full story

Yahoo Finance • last year

Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference

PASADENA, Calif., November 21, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference on... Full story

Yahoo Finance • last year

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

PASADENA, Calif., November 16, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to discuss its financial results for... Full story

Yahoo Finance • last year

Great week for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) institutional investors after losing 17% over the previous year

Key Insights Institutions' substantial holdings in Arrowhead Pharmaceuticals implies that they have significant influence over the company's share price 50% of the business is held by the top 20 shareholders Recent sales by insiders Ever... Full story

Yahoo Finance • 2 years ago

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Those holding Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shares would be relieved that the share price has rebounded 25% in the last thirty days, but it needs to keep going to repair the recent damage it has caused to investor portfolio... Full story

Yahoo Finance • 2 years ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results

PASADENA, Calif., November 14, 2022--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for... Full story

Yahoo Finance • 2 years ago

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016... Full story

Yahoo Finance • 3 years ago

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Is In A Strong Position To Grow Its Business

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. No... Full story

Yahoo Finance • 3 years ago

Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives

PASADENA, Calif., May 09, 2022--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today held a groundbreaking ceremony in Verona, WI, on the site which will house a new approximately 160,000 square foot drug manufacturing fac... Full story

Yahoo Finance • 3 years ago

Could The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companie... Full story